EuroCD 2025 – 8th European Cyclodextrin Conference

Today's cyclodextrin,

Today’s cyclodextrin is the first announcement of EUROCD25:

Save the date! We are happy to announce the 8th European Cyclodextrin Conference EuroCD2025, which will take place in Milan, Italy, from September 9 to 12, 2025.

Join us for this unique opportunity to exchange ideas with scholars worldwide and explore the innovative research, processes, methodologies, and applications that continue to shape the field of cyclodextrin chemistry.

We’re also excited to host the inaugural Thorsteinn Loftsson Award for cyclodextrin chemistry!
Visit our website to learn more about submitting a nomination.
EuroCD 2025 – 8th European Cyclodextrin Conference (9-12 September 2025): OVERVIEW · Indico Event Management @ DCMC – Politecnico di Milano (Indico)

Abstract submission is open. Please use the downloadable template and send your abstract via email only to eurocd2025@polimi.it.


We are looking forward to seeing you in Milan!

Andrea Mele & Francesco Trotta – Conference Chairs

Welcoming Fahad Khan Tareen from Università di Pavia: Collaborating on Innovative Drug Delivery with Cyclodextrins!

news

While some of our members enjoy secondments in Argentina and Leuven, we have the pleasure to host Fahad Khan Tareen from Università di Pavia Cristina Bonferoni‘s lab.

Fahad works with Balázs on some unique drug delivery applications with cyclodextrins (surprise!) and stays with us until next January.

It’s such a pleasure to work with so diligent and bright scientists, eager to learn and innovate.

Exceptional stability of the sugammadex-solasodine complex: Insights from experimental and theoretical studies

drug development

A new paper out!

Sugammadex (SGM) is the first cyclodextrin (CD)-based selective relaxant binding agent. We investigated its ability to capture natural aminosteroid phytotoxins, and assessed its potential as an antidote for intoxication.

SGM significantly increased cell survival and reduced Solasodine (the toxic alkaloid chosen as model compound) toxicity in mHippoE-14 mouse hippocampal embryonic cells, supporting the hypothesis that SGM could act as an antidote to SS’s toxic effects.

Special thanks for the fantastic teamwork:
Eszter Kalydi – Semmelweis University
Fanni Sebák, Éva Moussong József Kardos, Andrea Bodor Szabolcs Béni – Eötvös Loránd University
Béla Fiser – University of Miskolc
Babak Minofar – University of Lodz
Milo Malanga PhD – CarboHyde

Exceptional stability of the sugammadex-solasodine complex: Insights from experimental and theoretical studies – ScienceDirect

Impact of Methylated Cyclodextrin KLEPTOSE® CRYSMEB on Inflammatory Responses in Human In Vitro Models

Today's cyclodextrin

today’s cyclodextrin is a fanstastic study from dear friend Damien TRUFFIN from Roquette about the Impact of Methylated Cyclodextrin on Inflammatory Responses.

The results showed that KLEPTOSE® CRYSMEB can modulate the immune system in vitro and potentially manage vascular issues by stimulating the expression of molecules involved in the crosstalk between immune cells and other cell types.

It showed anti-inflammatory effects that were driven by the inhibition of pro-inflammatory cytokine secretion and could have different impacts on different tissue types.

Moreover, this cyclodextrin showed no clear impact on pro-resolving lipid mediators.

Additionally, it appeared that the mechanism of action of KLEPTOSE® CRYSMEB seems to not be shared by other well-known anti-inflammatory molecules.

Finally, KLEPTOSE® CRYSMEB may have an anti-inflammatory impact, which could be due to its effect on receptors such as TLR or direct complexation with LPS or PGE2, and conversely, this methylated cyclodextrin could stimulate a pro-inflammatory response involving lipid mediators and on proteins involved in communication with immune cells, probably via interaction with membrane cholesterol.

Impact of Methylated Cyclodextrin KLEPTOSE® CRYSMEB on Inflammatory Responses in Human In Vitro Models

Aomo Announces China’s NMPA Acceptance of NDA for Adamgammadex

Today's cyclodextrin, ,

Today’s cyclodextrin is about a Sugammadex competition.

Aomo Pharma, Inc. (the US branch of Adamerck) announced recently that the China National Medical Products Administration (NMPA) accepted its new drug application (NDA) for Adamgammadex (Aom0498).

Adamgammadex (Aom0498) is the next generation of specific neuromuscular blockade antagonists and has been shown to rapidly reverse neuromuscular blockades induced by rocuronium at various depths within 3 minutes. Compared with sugammadex, adamgammadex has a lower incidence of severe adverse reactions, such as allergic reactions, neuromuscular blockade recurrence, bradycardia, and laryngospasm, while maintaining more stable efficacy.

Adamgammadex has been developed globally; it has completed an End of Phase II Meeting with the FDA, and multiregional clinical trials (MRCTs) are scheduled to be launched in the US, Europe, and Japan to bring adamgammadex (Aom0498) into the global market.

Aomo Announces China’s NMPA Acceptance of NDA for Adamgammadex – Aomo Pharma Inc.

Formulation and investigation of differently charged β-cyclodextrin-based meloxicam potassium containing nasal powders

drug development, Today's cyclodextrin

Today’s cyclodextrin is a nice formulation study from one of the best Hungarian pharmaceutical universities, the University of Szeged, who study various excipients – CDs among others – that have an important role in nasal formulations to increase the permeability of the mucosa and prolong the residence time of the drug.

The charged cyclodextrin-based formulations showed significantly higher adhesive force values regardless of the presence of PVA. The drug release was fast and complete, and the permeation of meloxicam was enhanced.

Patricia Varga, Anett Németh, Scarlett Zeiringer, Eva Roblegg, Budai-Szűcs Mária, Csilla Balla-Bartos, Rita Ambrus

Formulation and investigation of differently charged β-cyclodextrin-based meloxicam potassium containing nasal powders – ScienceDirect

2-Hydroxypropyl-β-cyclodextrin (HPβCD) as a Potential Therapeutic Agent for Breast Cancer

Today's cyclodextrin

Today’s cyclodextrin:
If you follow CarboHyde, you saw that we recently added a new collaborative asset, KS-01, to our pipeline.

Here, you can find more info about this cyclodextrin that we developed together with the University of the Witwatersrand against triple-negative breast cancer and other types of cancer.

This collaboration marks a significant milestone in the fight against breast cancer, combining the strengths of two innovative organizations across continents. By pooling their resources, expertise, and networks, WITS and CarboHyde aim to bring this cutting-edge therapeutic to market, benefiting patients and healthcare systems worldwide.

Mandeep Kaur and her team already published a paper on this patented asset, so you can learn more about the science and check some available data here:

2-Hydroxypropyl-β-cyclodextrin (HPβCD) as a Potential Therapeutic Agent for Breast Cancer (mdpi.com)

How does cyclodextrin-based catalysis work?

carbohydrates,

Cyclodextrin-based catalysis leverages the unique structure of cyclodextrins, which form inclusion complexes with reactants, intermediates, or catalysts.

Their cavities create sterically restricted, non-polar environments that enhance reaction efficiency and selectivity, protecting unstable intermediates from side reactions. Through covalent or noncovalent modifications, cyclodextrins are combined with metal catalysis, achieving high yields and selectivity in one-pot reactions. These catalysts are also integrated into advanced materials like metal-organic frameworks, supporting unique applications.

As a result, cyclodextrin-based catalysis aligns well with green chemistry principles and offers significant contributions to sustainable chemical processes.

photo credit: 10.1139/v06-039

Monomeric, Oligomeric, Polymeric, and Supramolecular Cyclodextrins as Catalysts for Green Chemistry

Today's cyclodextrin

Today’s cyclodextrin is about using CDs as catalysts in green chemistry.

At CarboHyde we are committed to develop as green solutions as possible, industrially scalable and economical.

Makoto Komiyama from The University of Tokyo published a great summary of Monomeric, Oligomeric, Polymeric, and Supramolecular Cyclodextrins as Catalysts for Green Chemistry where he comprehensively covers recent developments of cyclodextrin-mediated chemical transformations for green chemistry.

How does cyclodextrin-based catalysis work?
Their most important feature is to form inclusion complexes with reactants, intermediates, and/or catalysts. As a result, their cavities serve as sterically restricted and apolar reaction fields to promote the efficiency and selectivity of reactions.

Monomeric, Oligomeric, Polymeric, and Supramolecular Cyclodextrins as Catalysts for Green Chemistry | Research (science.org)